India's Dr Reddy's Laboratories (REDY.NS) expects a healthy products pipeline in its key North American market in the fiscal year 2024-25, the generic drugmaker said on Tuesday, after it reported a fourth-quarter profit that beat expectations.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,